Developmental & Epileptic Encephalopathies (DEEs)
Ulysses Neuroscience has established the most comprehensive preclinical platform available for Developmental and Epileptic Encephalopathies. Our in-house transgenic mouse colonies, combined with validated behavioural phenotyping, seizure assessment protocols, advanced EEG platforms, and cross-species biomarker validation, provide an unmatched foundation for therapeutic development in these devastating paediatric conditions. What sets us apart is our integrated translational approach: we have demonstrated that key biomarkers—such as elevated plasma acetylated α-tubulin—are conserved between our mouse models and patient populations, enabling direct preclinical-to-clinical translation.
Explore Our Full Therapeutic Expertise
Beyond neuropsychiatric disorders, Ulysses Neuroscience delivers comprehensive preclinical and translational services across the spectrum of CNS conditions. Our integrated platform—combining behavioural pharmacology, advanced biomarker technologies, EEG, and human iPSC-derived models—enables seamless translation from bench to bedside across multiple therapeutic areas.
Neuropsychiatric
Diseases
- Depression & Treatment-Resistant Depression
- Anxiety Disorders
- Schizophrenia
Neurodegenerative Diseases
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis (ALS)
Neuromuscular
Diseases
- Charcot-Marie-Tooth Disease (CMT)
Neurodevelopmental Diseases
- CDKL5 Deficiency Disorder (CDD)
- Fragile X Syndrome (FXS)
- Epilepsy & Seizure Disorders
Psychedelics and
Neuroplastogens
- Classical psychedelics
- Next-generation non-hallucinogenic neuroplastogens.
